Dr. Mark Parry-Billings is biotech and pharmaceutical executive with an international track record of more than 30 years in leadership and senior R&D roles. Most recently, he served as Global Head of Drug Development at Chiesi (a global pharmaceutical company with a significant commitment to respiratory medicine). Prior to this, he served as CEO of Topigen Pharmaceuticals (a clinical stage biotech with gene silencing inhaled therapeutics), and has worked for pSivida (a NASDAQ-listed drug delivery company) and Innovata Biomed (a company focused on dry powder inhaler technology).